Figure 1From: Recent advances in systemic therapy. Advances in neoadjuvant (primary) systemic therapy with cytotoxic agentsStudy design of the GeparQuattro study. EC, epirubicin and cyclophosphamide; ER, estrogen receptor; OP, operation (surgery); PR, partial response; R, random assignment; T, trastuzumab; X, capecitabine. Reprinted with permission [17].Back to article page